Argenx's big bid to stay ahead
A crucial pivotal readout is approaching for the Belgian developer and Vyvgart, in a rare disease that represents the group’s riskiest move yet.
The biggest-selling pharma companies of 2023
Propelled by Covid Pfizer surges ahead, but more interest could fall on a cohort of companies driven by newcomer drugs lower down the list.
Clinical and corporate developments over the Christmas period
A decent showing for Pfizer/Roche in haemophilia sets up a rivalry with Uniqure/CSL, and a smattering of deals get done before the year end – and before JP Morgan.
When is big pharma no longer big pharma?
After a bruising few months for GSK, 17 global drug makers now have a higher market cap than the UK company.
An expensive new haemophilia gene therapy hits the US
The approval is good for CSL, and better for Uniqure.
Go or no go? Apellis eyes an FDA outcome
Immunogen and Uniqure are also set for Pdufa conclusions.